PMID- 31689867
OWN - NLM
STAT- MEDLINE
DCOM- 20191113
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 44
DP  - 2019 Nov
TI  - Elemene injection combined with transcatheter arterial chemoembolization for 
      unresectable hepatocellular carcinoma: A meta-analysis.
PG  - e17813
LID - 10.1097/MD.0000000000017813 [doi]
LID - e17813
AB  - BACKGROUND: To evaluate the short-term efficacy, long-term efficacy, and adverse 
      events (AEs) of elemene plus transcatheter arterial chemoembolization (TACE) in 
      comparison with TACE alone for the treatment of hepatocellular carcinoma (HCC). 
      METHODS: PubMed, EMBASE, the Cochrane Library, the Chinese Scientific Journal 
      Full-text Database, Wanfang Data, CBM, and VIP were searched by 2 reviewers using 
      the same search strategy for clinical studies on elemene plus TACE in the 
      treatment of HCC. These articles were screened according to pre-established 
      inclusion and exclusion criteria, and the qualities of the included studies were 
      assessed using the Newcastle-Ottawa scale. The primary outcomes were the 
      objective response rate (ORR), the 1-year survival rate and AEs. Review Manager 
      5.3 and Stata 15.0 were used for the meta-analysis. RESULTS: A total of 10 
      studies involving 543 patients (TACE + elemene = 277, TACE alone = 266) were 
      included. The results showed that the ORR was significantly improved in the 
      combined treatment group compared to the TACE alone group (odds ratio 
      [OR] = 2.72, 95% confidence interval [CI]: 1.84-4.00, P < .05). TACE + elemene 
      significantly increased the 1-year survival rate (OR = 2.79, 95% CI: 1.58-4.95, 
      P < .05). We also found no significant difference in gastrointestinal reactions 
      (OR = 0.97, 95% CI: 0.57-1.64, P = .90), fever (OR = 0.80, 95% CI: 0.37-1.71, 
      P = .56), or bone marrow suppression (OR = 0.73, 95% CI: 0.44-1.22, P = .23) 
      between the 2 groups. CONCLUSION: Based on current findings, TACE + elemene 
      injection may improve the ORR and the 1-year survival rate for HCC patients 
      compared to TACE alone. Arterial perfusion may be superior to intravenous guttae.
FAU - Yao, Yuan
AU  - Yao Y
AD  - Department of Interventional Radiology, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, PR China.
FAU - Chen, Jianjian
AU  - Chen J
FAU - Jiao, Dechao
AU  - Jiao D
FAU - Li, Yahua
AU  - Li Y
FAU - Zhou, Xueliang
AU  - Zhou X
FAU - Han, Xinwei
AU  - Han X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Sesquiterpenes)
RN  - 11029-06-4 (elemene)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Catheterization
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Humans
MH  - Injections, Intra-Arterial
MH  - Liver Neoplasms/*drug therapy
MH  - Sesquiterpenes/administration & dosage/adverse effects/*therapeutic use
PMC - PMC6946248
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/14 06:00
PMCR- 2019/11/01
CRDT- 2019/11/07 06:00
PHST- 2019/11/07 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/14 06:00 [medline]
PHST- 2019/11/01 00:00 [pmc-release]
AID - 00005792-201911010-00127 [pii]
AID - MD-D-19-03891 [pii]
AID - 10.1097/MD.0000000000017813 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Nov;98(44):e17813. doi: 10.1097/MD.0000000000017813.